<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00386750</url>
  </required_header>
  <id_info>
    <org_study_id>CCOA566A2412</org_study_id>
    <nct_id>NCT00386750</nct_id>
  </id_info>
  <brief_title>Safety of Artemether - Lumefantrine, and Other Malaria Drugs and Their Effect on the Auditory Function</brief_title>
  <official_title>An Open-label, Single-center Study of the Effects of Co-artemether, Atovaquone-proguanil, and Artesunate-mefloquine on Auditory Function Following the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Patients 12 Years of Age or Older.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      THIS STUDY IS NOT ENROLLING PATIENTS IN THE USA.

      To evaluate the effects of artemether/ lumefantrine on the auditory function.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Auditory abnormalities at Day 7 assessed by Auditory Brainstem Response (ABR) wave form latencies (a type of hearing test).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of auditory changes following 3 days of treatment with artemether-lumefantrine at Days 7, 28, and 42 days assessed by pure tone thresholds assessments (a type of hearing test)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in auditory function with a non-ACT (artemisinin combined therapy) antimalarial (Malarone, atovaquone-proguanil) and another ACT combination (artesunate-mefloquine) assessed by pure tone thresholds (a type of hearing test)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between changes in auditory function and drug exposure.</measure>
  </secondary_outcome>
  <enrollment>265</enrollment>
  <condition>Malaria</condition>
  <condition>Falciparum</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  12 years of age or older

          -  P. falciparum parasitemia between 50 and 100,000 parasites/μl

          -  History of fever or presence of fever (temperature ≥ 37.5°C)

        Exclusion Criteria

          -  Signs/symptoms of severe/complicated malaria

          -  Ingestion of various antimalarial drugs, or antibiotics in the previous 2 weeks to 2
             months

          -  History of any drug-related hearing impairment.

          -  Abnormal hearing function at study entry

          -  Exposure to sustained loud noises, by self-report, within the past 24 hours. --
             Present ear problems

        (Other protocol-defined inclusion/exclusion criteria may apply.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2006</study_first_submitted>
  <study_first_submitted_qc>October 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2006</study_first_posted>
  <last_update_submitted>April 25, 2012</last_update_submitted>
  <last_update_submitted_qc>April 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>hearing</keyword>
  <keyword>co-artemether</keyword>
  <keyword>auditory</keyword>
  <keyword>Plasmodium falciparum</keyword>
  <keyword>marsh fever</keyword>
  <keyword>Plasmodium infections</keyword>
  <keyword>remittent fever</keyword>
  <keyword>paludism</keyword>
  <keyword>artemether</keyword>
  <keyword>artemisinins</keyword>
  <keyword>benflumetol</keyword>
  <keyword>lumefantrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

